Definition and epidemiology
Bipolar disorder is a psychiatric illness marked by pathological mood elevation (mania or hypomania) alternating with periods of depression and normal mood. It is classified into subtypes: Bipolar I disorder requires at least one manic episode (may or may not include depressive episodes), Bipolar II disorder involves at least one hypomanic episode and one major depressive episode (but no full manic episodes), and Cyclothymic disorder features chronic fluctuating mood with hypomanic and depressive symptoms that do not meet full criteria.
The lifetime prevalence is approximately 1–2%, with Bipolar I and Bipolar II each affecting roughly 0.5–1% of the population. Age of onset typically ranges from late teens to mid-20s, though diagnosis is often delayed by several years. The disorder affects men and women equally, though Bipolar II may be slightly more common in women. There is no significant variation by ethnicity, but expression and help-seeking behavior may differ across cultures.
- Bipolar I requires at least one manic episode (≥7 days); Bipolar II requires hypomania (≥4 days) plus major depression, no full mania.
- Manic episode: elevated mood plus ≥3 of DIG FAST (Distractibility, Insomnia/decreased sleep, Grandiosity, Flight of ideas, Activity increase, Speech pressured, Thoughtlessness/risky behavior).
- Antidepressants alone can trigger mania; always combine with mood stabilizer in bipolar depression.
- Lithium is first-line for maintenance and reduces suicide risk; monitor levels, renal function, and thyroid.
- Valproate is highly teratogenic (neural tube defects); avoid in women of childbearing age if possible.
- Bipolar disorder has 70–90% heritability, one of the highest among psychiatric disorders.
- Suicide risk is 10–15% lifetime; highest during depressive and mixed episodes.
- ECT is highly effective for severe or refractory mania and bipolar depression.
Etiology and risk factors
Bipolar disorder is a multifactorial condition with strong genetic and neurobiological components.
Genetic factors
- Heritability is estimated at 70–90%, making it one of the most heritable psychiatric disorders.
- First-degree relatives of affected individuals have a 5–10 times higher risk.
- Twin studies show concordance rates of approximately 40–70% in monozygotic twins and 5–10% in dizygotic twins.
- Multiple susceptibility genes have been identified, including those involved in calcium signaling, circadian rhythm regulation, and neurotransmitter pathways.
Neurobiological factors
- Dysregulation of monoaminergic neurotransmitter systems (dopamine, serotonin, norepinephrine).
- Abnormalities in brain structure and function, particularly involving the prefrontal cortex, amygdala, and hippocampus.
- Circadian rhythm disruption and sleep-wake cycle abnormalities.
Environmental and psychosocial factors
- Stressful life events can precipitate mood episodes, especially early in the illness.
- Substance use, particularly stimulants, alcohol, and cannabis, can trigger or worsen episodes.
- Sleep disruption is a powerful trigger for manic episodes.
- Seasonal patterns: some patients experience mood episodes with seasonal changes.
- Childhood trauma and adverse experiences may increase vulnerability.
Pathophysiology
The pathophysiology of bipolar disorder involves complex interactions between genetic predisposition, neurotransmitter dysregulation, and structural brain changes.
Neurotransmitter systems
- Dopamine: hyperactivity in mesolimbic pathways during mania contributes to euphoria, increased goal-directed activity, and psychotic features.
- Serotonin and norepinephrine: imbalances contribute to mood instability and depressive episodes.
- Glutamate and GABA: excitatory-inhibitory imbalance may underlie mood cycling.
Neuroanatomical changes
- Reduced gray matter volume in prefrontal cortex and hippocampus.
- Enlarged ventricles in some patients.
- White matter abnormalities affecting neural connectivity.
Circadian rhythm dysfunction
- Dysregulation of circadian clock genes affects sleep-wake cycles, hormone secretion, and mood regulation.
- Disruption of melatonin and cortisol rhythms.
Mitochondrial and cellular dysfunction
- Impaired cellular energy metabolism and oxidative stress.
- Altered intracellular calcium signaling.
- Reduced neuroplasticity and neurogenesis.
These mechanisms interact to produce the cyclical mood disturbances characteristic of bipolar disorder.
Clinical features
Bipolar disorder presents with distinct mood episodes that differ qualitatively from normal mood variations.
Manic episode
A manic episode lasts at least 7 days (or any duration if hospitalization is required) and includes elevated, expansive, or irritable mood plus three or more of the following (four if mood is only irritable):
- Inflated self-esteem or grandiosity (may be delusional)
- Decreased need for sleep (feels rested after 3 hours)
- More talkative than usual or pressure to keep talking
- Flight of ideas or racing thoughts
- Distractibility
- Increase in goal-directed activity or psychomotor agitation
- Excessive involvement in risky activities (spending sprees, sexual indiscretions, foolish investments)
The episode causes marked functional impairment, may include psychotic features, or requires hospitalization. Judgment is severely impaired.
Hypomanic episode
Hypomania resembles mania but is less severe, lasts at least 4 consecutive days, and does not cause marked functional impairment or require hospitalization. Psychotic features are absent. The change is observable by others but the person can usually continue daily activities.
Major depressive episode
Lasts at least 2 weeks with five or more symptoms including depressed mood or anhedonia:
- Depressed mood most of the day
- Markedly diminished interest or pleasure (anhedonia)
- Significant weight change or appetite disturbance
- Insomnia or hypersomnia
- Psychomotor agitation or retardation
- Fatigue or loss of energy
- Feelings of worthlessness or excessive guilt
- Diminished concentration or indecisiveness
- Recurrent thoughts of death or suicidal ideation
Mixed features
Some episodes have simultaneous manic and depressive symptoms, creating particularly distressing states with high suicide risk.
Course and patterns
- Rapid cycling: four or more mood episodes per year (occurs in 10–20% of patients).
- Most patients spend more time depressed than manic.
- Untreated episodes typically last weeks to months.
- Frequency and duration of episodes often increase over time without treatment.
Diagnosis
Diagnosis is clinical, based on psychiatric history and mental status examination. No laboratory test or imaging study is diagnostic, but investigations help rule out medical causes of mood symptoms.
Diagnostic criteria (DSM-5)
Bipolar I disorder: at least one manic episode. Depressive episodes are common but not required for diagnosis.
Bipolar II disorder: at least one hypomanic episode and at least one major depressive episode, with no manic episodes.
Cyclothymic disorder: chronic (at least 2 years) fluctuating mood with numerous hypomanic and depressive symptoms that do not meet full criteria for episodes.
Clinical assessment
- Detailed psychiatric history: careful documentation of mood episodes, duration, severity, and functional impact.
- Collateral information from family or friends is crucial, as patients may not recognize or recall manic symptoms.
- Mental status examination during evaluation.
- Screening tools: Mood Disorder Questionnaire (MDQ), Hypomania Checklist (HCL-32).
Investigations
- Thyroid function tests (TSH, free T4): hypothyroidism and hyperthyroidism mimic mood disorders.
- Complete blood count, electrolytes, renal and liver function: baseline before medication.
- Urine drug screen: stimulants and other substances can cause manic symptoms.
- Brain imaging (CT or MRI) if first episode with atypical features, focal neurological signs, or sudden onset in older adults to exclude structural lesions, dementia, or stroke.
- EEG if seizure disorder is suspected.
Diagnosis is often delayed, with patients initially misdiagnosed as having unipolar depression (especially in Bipolar II) or other psychiatric conditions.
Differential diagnosis
Many conditions can mimic or coexist with bipolar disorder.
Psychiatric differentials
- Major depressive disorder: distinguished by absence of manic or hypomanic episodes; critical to obtain history of past mood elevation.
- Schizoaffective disorder: psychotic symptoms occur both during and outside of mood episodes.
- Schizophrenia: psychosis is primary, mood symptoms are secondary or absent.
- Borderline personality disorder: rapid mood shifts last hours, not days; no distinct episodes with sustained elevated mood.
- Attention-deficit/hyperactivity disorder (ADHD): chronic symptoms from childhood, no episodic pattern, no true mood elevation.
- Substance use disorders: stimulants, alcohol, cannabis, and other drugs can cause manic or depressive symptoms.
Medical differentials
- Hyperthyroidism: anxiety, irritability, insomnia, weight loss.
- Hypothyroidism: depressive symptoms, fatigue, cognitive slowing.
- Cushing syndrome: mood lability, depression, psychosis.
- Multiple sclerosis: mood changes with neurological deficits.
- Brain tumors or stroke: especially frontal lobe lesions.
- Temporal lobe epilepsy: complex partial seizures with mood and behavioral changes.
- HIV, neurosyphilis: secondary psychiatric manifestations.
- Medication-induced: corticosteroids, stimulants, dopamine agonists, antidepressants (can trigger mania).
Distinguishing features
Bipolar disorder involves distinct episodes with clear changes from baseline mood and functioning. Episodes last days to weeks, unlike the brief mood shifts in personality disorders or the chronic symptoms of ADHD.
Management
Treatment combines pharmacotherapy, psychotherapy, and psychosocial support. Goals are to treat acute episodes, prevent recurrence, and improve functioning.
Acute mania
First-line agents: mood stabilizers and antipsychotics.
- Lithium: highly effective mood stabilizer; requires monitoring of levels, renal and thyroid function.
- Valproate (valproic acid, divalproex): effective for acute mania; monitor liver function and blood counts. Black box warnings: hepatotoxicity (fatal hepatic failure, especially in children under 2 and patients with mitochondrial disorders), pancreatitis (which can be fatal), and teratogenicity (neural tube defects and other major congenital malformations).
- Atypical antipsychotics: olanzapine, risperidone, quetiapine, aripiprazole, asenapine are effective monotherapy or adjuncts.
- Carbamazepine: alternative mood stabilizer. Black box warnings: serious and sometimes fatal dermatologic reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (risk increased in patients with HLA-B*1502 allele, particularly in Asian populations), and aplastic anemia and agranulocytosis.
Severe mania: combination therapy (e.g., lithium or valproate plus antipsychotic) or electroconvulsive therapy (ECT) if refractory or life-threatening.
Benzodiazepines (lorazepam, clonazepam) for agitation and insomnia during acute episodes.
Acute bipolar depression
First-line:
- Quetiapine or lurasidone: atypical antipsychotics with evidence for bipolar depression.
- Lamotrigine: effective for maintenance, slower onset for acute treatment. Black box warning: serious and potentially life-threatening skin rashes including Stevens-Johnson syndrome and toxic epidermal necrolysis (risk highest in first 8 weeks, with rapid dose escalation, concurrent valproate use, or in children).
- Lithium or valproate can be continued or optimized.
Caution with antidepressants: SSRIs and other antidepressants may trigger mania or rapid cycling; use cautiously and only with mood stabilizer coverage. Not recommended as monotherapy.
Electroconvulsive therapy (ECT): highly effective for severe, refractory, or psychotic depression.
Maintenance treatment
Long-term mood stabilizer therapy is essential to prevent recurrence.
- Lithium: gold standard for maintenance; reduces suicide risk significantly.
- Valproate, lamotrigine, carbamazepine: alternative or adjunctive agents.
- Atypical antipsychotics: quetiapine, aripiprazole, olanzapine for maintenance.
Monitoring:
- Lithium: serum levels, renal function (creatinine), thyroid function (TSH), ECG.
- Valproate: liver function tests, complete blood count.
- Carbamazepine: complete blood count, liver function tests; consider HLA-B*1502 screening before initiation in at-risk populations.
- Lamotrigine: monitor for rash, especially in first 8 weeks.
- Atypical antipsychotics: weight, glucose, lipids (metabolic syndrome risk).
Psychotherapy and psychosocial interventions
- Psychoeducation: understanding illness, recognizing early warning signs, medication adherence.
- Cognitive behavioral therapy (CBT): managing depressive symptoms, thought patterns.
- Interpersonal and social rhythm therapy (IPSRT): stabilizing daily routines and sleep-wake cycles.
- Family-focused therapy: improving communication, reducing family stress.
Lifestyle and supportive measures
- Regular sleep-wake schedule: critical for preventing manic episodes.
- Avoid alcohol and recreational drugs.
- Stress management and routine.
- Support groups and peer support.
Special considerations
- Pregnancy: avoid valproate (teratogenic). Lithium has risks but may be continued with careful monitoring if benefits outweigh risks. Atypical antipsychotics and lamotrigine are alternatives.
- Rapid cycling: may respond better to valproate or lamotrigine than lithium; avoid antidepressants.
Long-term adherence to treatment is challenging; collaborative care and psychoeducation improve outcomes.
Complications and prognosis
Complications
- Suicide: lifetime risk is 10–15%, approximately 20 times higher than the general population. Risk is highest during depressive and mixed episodes.
- Substance use disorders: occur in 40–60% of patients; worsen course and treatment outcomes.
- Medical comorbidities: increased rates of cardiovascular disease, diabetes, obesity, and metabolic syndrome (partly treatment-related).
- Cognitive impairment: deficits in executive function, memory, and attention, even between episodes.
- Functional impairment: high rates of unemployment, relationship difficulties, disability.
- Treatment non-adherence: leads to relapse, hospitalization, and poorer outcomes.
- Legal and financial problems: during manic episodes due to impulsivity and poor judgment.
Prognosis
Bipolar disorder is a chronic, lifelong illness with a relapsing-remitting course. Prognosis varies widely:
- With treatment: many patients achieve good symptom control and functional recovery. Maintenance treatment reduces relapse rates by approximately 50%.
- Without treatment: high rates of recurrence, progressive worsening, and functional decline.
- Predictors of poorer prognosis: early onset, rapid cycling, psychotic features, comorbid substance use, poor medication adherence, lack of social support.
- Lithium: associated with reduced suicide risk and mortality.
Functional recovery lags behind symptomatic recovery; many patients have ongoing subsyndromal symptoms and work or relationship difficulties even when not in full episodes.
Long-term outcomes: approximately one-third achieve good functional outcomes, one-third have moderate impairment, and one-third have severe ongoing disability. Early diagnosis, consistent treatment, and psychosocial support improve outcomes significantly.
DIG FAST for manic episode symptoms: Distractibility, Insomnia (decreased need for sleep), Grandiosity, Flight of ideas, Activity increase, Speech (pressured), Thoughtlessness (risky behavior).
Practice questions
1. A 24-year-old woman is brought to the emergency department by her roommate. Over the past 5 days, she has slept only 2–3 hours per night but feels more energetic than ever. She has been talking incessantly, starting multiple new projects, and spent $3000 on online shopping despite being a student with limited income. She believes she is destined to become a famous artist. Her roommate reports that 6 months ago the patient was very depressed and missed classes for 3 weeks. She has no medical history and takes no medications. On examination, she is euphoric, speaks rapidly, and is easily distracted. Which of the following is the most appropriate initial pharmacologic treatment?
2. A 32-year-old man with a 10-year history of bipolar disorder has been stable on lithium for 3 years. He presents for routine follow-up. Laboratory results show: serum creatinine 1.8 mg/dL (baseline 1.0 mg/dL), lithium level 1.1 mEq/L (therapeutic range 0.6–1.2), and TSH 8.5 mIU/L (normal 0.5–5.0). He reports no mood symptoms but has gained 10 pounds in 6 months and feels mildly fatigued. Which of the following is the most appropriate next step?
3. A 28-year-old woman presents to her primary care physician with a 3-week history of depressed mood, loss of interest in activities, insomnia, poor concentration, and feelings of worthlessness. She has no suicidal ideation. Her medical history is notable for a brief hospitalization 2 years ago when she was 'overly energetic' for several days, spent all her savings impulsively, and required sedation. She was started on medication but stopped taking it after 6 months. Which of the following is the most appropriate initial treatment for her current episode?
Frequently asked questions
What causes bipolar disorder?
Bipolar disorder results from a combination of genetic, neurobiological, and environmental factors. It is highly heritable (70–90%), with first-degree relatives having 5–10 times higher risk. Dysregulation of neurotransmitters (dopamine, serotonin, norepinephrine), structural brain abnormalities, and circadian rhythm dysfunction contribute to mood cycling. Environmental triggers like stress, sleep disruption, and substance use can precipitate episodes in genetically vulnerable individuals.
What are the first symptoms of bipolar disorder?
Bipolar disorder typically begins in late adolescence to early adulthood. Initial symptoms often include a depressive episode, which may be misdiagnosed as unipolar depression. The first manic or hypomanic episode usually follows months to years later, revealing the bipolar nature. Early signs of mania include decreased need for sleep, increased energy, racing thoughts, impulsive behavior, and mood elevation or irritability that is uncharacteristic for the person.
How is bipolar disorder diagnosed?
Diagnosis is clinical, based on psychiatric history and mental status examination using DSM-5 criteria. Bipolar I requires at least one manic episode (lasting ≥7 days), while Bipolar II requires at least one hypomanic episode (≥4 days) and one major depressive episode. Collateral history from family or friends is essential, as patients may not recall or recognize manic symptoms. Laboratory tests (thyroid function, drug screen) and brain imaging help rule out medical causes but are not diagnostic for bipolar disorder itself.
Is bipolar disorder curable?
Bipolar disorder is not curable but is highly treatable. It is a chronic, lifelong condition requiring ongoing management with mood stabilizers (lithium, valproate, lamotrigine) or atypical antipsychotics, plus psychotherapy and lifestyle modifications. With consistent treatment, many patients achieve good symptom control, prevent relapses, and maintain normal functioning. Lithium, in particular, reduces suicide risk and improves long-term outcomes. Treatment adherence and early intervention are critical for prognosis.
Bipolar I vs Bipolar II — what is the difference?
The key difference is episode severity. Bipolar I disorder requires at least one manic episode (lasting ≥7 days with severe functional impairment, possible psychosis, or hospitalization). Depressive episodes are common but not required for diagnosis. Bipolar II disorder involves at least one hypomanic episode (≥4 days, less severe, no marked impairment) and at least one major depressive episode, but no full manic episodes. Bipolar II patients typically spend more time depressed and may have higher suicide risk despite milder mood elevations.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: F31
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.